SRPK1 inhibition in prostate cancer: A novel anti-angiogenic treatment through modulation of VEGF alternative splicing

Prostate cancer remains one of the leading causes of cancer death in men around the world, regardless of intense research and development of novel therapies in the last 10 years. One of the new avenues that has been tested ⿿ inhibition of angiogenesis ⿿ has been disappointing so far in clinical stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Mavrou, Athina, Oltean, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Invited Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876767/
https://www.ncbi.nlm.nih.gov/pubmed/26995304
http://dx.doi.org/10.1016/j.phrs.2016.03.013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876767/
https://www.ncbi.nlm.nih.gov/pubmed/26995304
http://dx.doi.org/10.1016/j.phrs.2016.03.013

Ejemplares similares